Trump Pushes Cannabis Rescheduling as Hemp CMS Issues Play Out in Federal Court

News > Technology News

Audio By Carbonatix

2:30 PM on Tuesday, April 21

The Associated Press

"This isn't about being anti-cannabis. It's about being pro-science. MMJ International Holdings followed the FDA botanical drug pathway from the beginning, and <_apxh3a_a rel="nofollow" href="https://youtu.be/tEi5Wg72jVk">we are working through the same CMC requirements every pharmaceutical developer must meet. Federal healthcare programs should not introduce cannabinoid products into the Medicare population until those same standards are satisfied."Why the SAM Lawsuit Against CMS Is Likely to Prevail - and Why It Matters for MMJ International Holdings WASHINGTON, DC / <_apxh3a_a href='https://www.accessnewswire.com/'>ACCESS Newswire / April 21, 2026 / A federal lawsuit challenging the Centers for Medicare & Medicaid Services' decision to introduce hemp-derived cannabinoid access pathways into Medicare connected care models is rapidly becoming one of the most consequential cannabis policy cases in years.<_apxh3a_a href="https://app.accessnewswire.com/imagelibrary/23e113dd-5044-4f59-b681-dbbb1386ef24/image-4-20-26-at-936am.png" rel="nofollow"> The litigation-supported by clinicians, constitutional scholars, and aligned with the regulatory position long advanced by MMJ International Holdings-centers on a simple but foundational principle:Federal healthcare reimbursement must follow scientific validation-not precede it.If the court agrees, the decision could reshape how botanical therapies enter federal healthcare systems and reinforce the FDA clinical-trial pathway that MMJ has followed from the beginning.Why the Plaintiffs' Case Is StrongThe lawsuit raises several arguments that courts historically take seriously under administrative law.1. CMS cannot bypass the FDA drug-approval frameworkThe United States already has a defined system for introducing therapies into federally funded care:the FDA clinical-trial pathway.When agencies introduce therapeutic products outside that pathway-especially for a vulnerable population like Medicare beneficiaries-it creates a regulatory conflict that courts often scrutinize closely.The issue is not cannabis.It is process.2. Medicare populations require heightened safety justificationMedicare primarily serves Americans age 65 and older.Introducing cannabinoid products into this population without:clinical pharmacokinetic validationdose-response understandingdrug-interaction datastability-controlled formulation standardsraises serious policy concerns.Courts routinely examine whether agencies adequately evaluated risk when programs affect medically vulnerable populations.3. CMS appears to have avoided formal rulemaking requirementsUnder the Administrative Procedure Act (APA), agencies generally must conduct:notice-and-comment rulemakingmarket-impact evaluationstakeholder participationbefore implementing policies with national clinical implications.If the court determines those steps were insufficient, the program becomes legally vulnerable.4. Federal reimbursement before FDA approval distorts pharmaceutical development incentivesThis is one of the strongest arguments in the case.Allowing reimbursement for non-IND cannabinoid products while companies like MMJ are actively completing FDA Chemistry, Manufacturing and Controls (CMC) requirements creates:unequal regulatory treatmentmarket distortionreduced incentives for clinical trialsCourts take competitive harm arguments seriously when federal agencies alter regulatory expectations mid-stream.Why a Favorable Outcome Matters for MMJ International HoldingsMMJ's position in the cannabis sector has always been different from the retail marketplace model.From the beginning, the company pursued:FDA Investigational New Drug submissionsorphan-drug designation for Huntington's diseasestandardized cannabinoid soft-gel formulation developmentDEA analytical laboratory complianceDEA bulk-manufacturing authorization for clinical supplyToday, MMJ continues working with the FDA to resolve remaining Chemistry, Manufacturing and Controls (CMC)questions associated with its cannabinoid clinical program.That work reflects exactly the regulatory safeguards the CMS lawsuit seeks to protect.The Case Reinforces the FDA Botanical-Drug Framework MMJ Followed From the StartThe FDA Botanical Drug Development Guidance requires:batch reproducibilityvalidated chemistrystability-controlled dosage formscontaminant testingclinical-trial evidenceThese are not optional standards.They are the foundation of modern pharmaceutical safety policy.MMJ's development strategy anticipated that federal healthcare programs would ultimately rely on this framework before adopting cannabinoid therapies.The lawsuit asks the court to confirm exactly that principle.Why the Hemp Industry's Regulatory Experience Supports the Plaintiffs' ArgumentRecent federal and state responses to intoxicating hemp products demonstrate what happens when cannabinoid markets expand without pharmaceutical-grade controls.Escalating THC potencynon-standardized formulationslabeling variabilityabsence of clinical validationhave already triggered tightening federal restrictions scheduled to take effect later this year.As one policy analysis noted, regulators increasingly concluded that loophole-driven cannabinoid markets created inconsistent safety expectations across jurisdictions.The CMS case addresses whether those same structural risks should enter Medicare-connected care pathways.Why the Litigation Signals Strength-Not Risk-for MMJ's Clinical ProgramsSome observers assume litigation involving cannabinoid policy creates uncertainty for pharmaceutical developers.In reality, the opposite is true.If the court confirms that federal healthcare adoption must follow FDA validation:MMJ's regulatory strategy becomes more valuableclinical-trial pathways become more centralCMC compliance becomes more importantand pharmaceutical cannabinoids gain clearer differentiation from retail productsThis strengthens the long-term positioning of federally compliant botanical-drug developers.Science First, Reimbursement SecondThe CMS litigation ultimately asks a single question:Should taxpayer-funded healthcare programs introduce botanical cannabinoid therapies before those therapies meet FDA drug-development standards?MMJ International Holdings has answered that question consistently since entering the cannabis sector.Science must come first.And if the court agrees, the decision will not simply affect one CMS program-it will help define the regulatory foundation for the future of cannabinoid medicine in the United States.Madison Hisey<_apxh3a_a rel="nofollow" href="mailto:[email protected]">[email protected]203-231-8583SOURCE: MMJ International HoldingsView the original <_apxh3a_a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/trump-pushes-cannabis-rescheduling-as-hemp-cms-issues-play-out-in-fed-1159540'>press release on ACCESS Newswire